Morning Overview on MSN
A phase 1/2 trial just reported exceptional disease control on pancreatic cancer using daraxonrasib — a targeted drug aimed at the mutation doctors once called untreat…
For more than three decades, oncologists have watched the same story play out with pancreatic cancer. A patient’s tumor is ...
HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
SAN CARLOS, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of ...
A phase 1 study of fixed-dose regimens of serplulimab, an anti-PD-1 antibody, in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
REDWOOD CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today ...
-- VAX-31 is Designed to Provide Coverage for Approximately 95% of Invasive Pneumococcal Disease Circulating in the U.S. Adult Population -- About the VAX-31 Phase 1/2 StudyThe VAX-31 Phase 1/2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results